awaiting key results for enzalutamide and apalutamide in nmcrpc
Published 5 years ago • 151 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
3:19
live long and prosper: enzalutamide for nmcrpc
-
3:40
this is spartan! apalutamide treatment for nmcrpc
-
2:17
enzalutamide for biochemically recurrent prostate cancer | nejm
-
17:59
what is oligometastatic prostate cancer?
-
5:19
xtandi patient stories
-
8:16
37 prostatic calcifications are associated with storage luts and nocturia in patients with benign
-
0:42
enzalutamide in the non-metastatic setting for crpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
2:11
straightforward study design: spartan trial of apalutamide for nmcrpc
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
6:42
titan trial
-
5:20
apalutamide in treating nonmetastatic crpc
-
1:34
dr. chi on the titan trial results in metastatic castration-sensitive prostate cancer
-
1:23
dr. saad on the safety profile of apalutamide in m0crpc
-
6:40
updated overall survival outcomes in enzamet (anzup 1304)
-
1:59
enzalutamide (mdv3100): key drug for advanced prostate cancer treatment | glpbio
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
2:25
advances in nmcrpc
-
9:51
overall survival data presented at asco 2020 for nmcrpc